Penumbra (NYSE:PEN) Director Sells $32,822.00 in Stock
Penumbra (NYSE:PEN) Director Harpreet Grewal sold 100 shares of the company's stock on April 2nd for $32,822.00, reducing his stake by 1.13% to 8,719 shares. This transaction follows a previous sale in January. The company recently missed quarterly EPS estimates but exceeded revenue expectations, and analysts currently rate the stock as "Hold."
Penumbra (NYSE: PEN) director sells 100 shares under Rule 10b5-1 plan
Penumbra Inc. director Harpreet Grewal sold 100 shares of common stock at $328.22 per share on April 2, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction leaves Grewal with 8,719 shares directly held, with a portion of these still subject to vesting conditions. The sale was an open-market transaction and is considered neutral in its filing impact but negative in sentiment.
Grewal Harpreet, Penumbra director, sells $32,822 in stock
Penumbra Inc. director Grewal Harpreet sold 100 shares of the company's common stock for $32,822 on April 2, 2026, after the stock surged 32% in the last six months. This transaction occurred under a Rule 10b5-1 trading plan, leaving Grewal with 8,719 shares. The sale follows recent robust financial performance for Penumbra, including strong Q4 2025 revenues, and news of its acquisition by Boston Scientific for $374 per share.
JP Morgan Maintains Penumbra (PEN) Neutral Recommendation
J.P. Morgan has reiterated its Neutral rating on Penumbra (PEN), maintaining a price target of $170. The report notes Penumbra's strong performance in both their neurovascular and peripheral vascular businesses, with revenue growth driven by volume gains and new product introductions. Despite positive Q4 2023 results and optimistic Q1 2024 guidance, the firm advises caution due to current valuation and potential market competition.
PEN PE Ratio & Valuation, Is PEN Overvalued
Penumbra Inc (PEN) is currently considered to be in a "Fair zone" based on its forward PS ratio of 7.13 compared to its five-year average. The fair price for PEN is estimated to be between $265.56 and $436.37. Although its P/S ratio is 93.75% above the industry average, this premium is deemed sustainable due to robust revenue growth.
SG Americas Securities LLC Has $3.46 Million Stake in Penumbra, Inc. $PEN
SG Americas Securities LLC significantly increased its stake in Penumbra, Inc. (NYSE:PEN) by 144.4% in the fourth quarter, now owning 11,111 shares valued at $3.455 million. Despite this increased institutional interest, Penumbra missed its EPS estimates for the last quarter, though revenue exceeded expectations. Analysts have largely downgraded the stock, with a current consensus "Hold" rating and an average price target of $361.69.
[144] Penumbra Inc SEC Filing
Penumbra, Inc. filed a Rule 144 notice detailing proposed sales of Common Stock. The filing indicates a 100-share lot linked to Fidelity Brokerage Services LLC valued at $32,822.00, and a separate entry for 186 shares associated with Grewal Harpreet on January 6, 2026, with a value of $58,151.04. This is a routine disclosure and not an executed market-moving transaction.
Allspring Global Investments Holdings LLC Sells 6,471 Shares of Penumbra, Inc. $PEN
Allspring Global Investments Holdings LLC reduced its stake in Penumbra, Inc. by 1.8%, selling 6,471 shares and holding 358,626 shares valued at $110.97 million by the end of the quarter. Penumbra reported a surprising EPS loss of ($0.37) but exceeded revenue estimates with $385.39 million, representing a 22.2% year-over-year increase. The stock has a consensus "Hold" rating with an average target price of $361.69, though some analysts have recently upgraded or downgraded their ratings.
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound?
This article from MSN discusses Penumbra (PEN) and its 1.6% stock price decline since its last earnings report. It poses the question of whether the stock can rebound. Without further article content, specific details about the reasons for the drop or potential rebound factors are not available.
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound?
Penumbra (PEN) has seen a 1.6% decline in its stock price since its last earnings report. Investors are anticipating whether the company can reverse this trend in its upcoming report. The stock's performance post-earnings will be crucial in determining its short-term trajectory.
Vanguard disaggregates holdings; reports 0 shares in Penumbra (PEN)
Vanguard has filed an amended Schedule 13G/A, reporting 0 shares beneficially owned in Penumbra Inc., representing 0% of the common stock. This change follows an internal realignment effective January 12, 2026, wherein certain Vanguard subsidiaries and business divisions will now report beneficial ownership separately. The filing clarifies that The Vanguard Group no longer holds beneficial ownership over securities reported by these disaggregated entities.
Reasons to Keep Penumbra Shares in Your Portfolio at This Time
Penumbra, Inc. (PEN) is poised for growth due to its expanding product line, including new thrombectomy solutions and vascular access systems, and its efforts to broaden international reach. Despite potential headwinds from currency fluctuations and macroeconomic pressures, the company has consistently exceeded earnings expectations. The article highlights Penumbra's strong product innovation, international expansion, and provides an optimistic outlook for its stock, while also mentioning alternative investment opportunities in the medical sector.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Penumbra, Inc. (PEN) is poised for growth due to its expanding product portfolio, particularly in thrombectomy and embolization technologies, and successful global expansion efforts with significant international revenue. However, macroeconomic concerns outside the U.S. and unfavorable foreign exchange rates pose operational and financial risks, impacting near-term profitability despite strong past earnings surprises. The article suggests retaining PEN stock given its positive outlook despite these challenges.
Reasons to Keep Penumbra Shares in Your Portfolio at This Time
Penumbra, Inc. (PEN) is expected to grow due to its expanding product line and international reach, despite potential challenges from currency fluctuations and a sluggish global economy. The company has consistently outperformed earnings expectations and its stock has risen significantly over the past year. Key growth drivers include innovative thrombectomy solutions, new product launches like Lightning Bolt 6X/7 and Element Vascular Access System, and successful ongoing international expansion, which accounted for over 22% of its 2025 revenue.
Penumbra Inc Stock: Boston Scientific Merger Agreement Reshapes Investor Outlook for US70975L1070 Sh
Boston Scientific's $14.8 billion agreement to acquire Penumbra Inc, announced on January 14, 2026, is set to transform the medical device landscape. Penumbra, a leader in neurovascular and peripheral vascular devices, is valued for its innovative thrombectomy and embolization technologies. The merger is expected to create significant synergies in research, development, and global distribution, enhancing Boston Scientific's neurovascular portfolio and offering a clear exit path for Penumbra shareholders.
Discipline and Rules-Based Execution in PEN Response
This article analyzes Penumbra Inc. (NYSE: PEN) using AI models, identifying a neutral near and mid-term outlook but a strong long-term positive bias. It highlights an exceptional risk-reward setup targeting a 9.8% gain and provides three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Congress Asset Management Co. Trims Stake in Penumbra, Inc. $PEN
Congress Asset Management Co. reduced its stake in Penumbra, Inc. (NYSE:PEN) by 10.9% in the fourth quarter, selling 46,822 shares and retaining 382,350 shares valued at $118.88 million. This move comes amidst various other institutional investor changes in Penumbra holdings and several recent analyst downgrades, though the stock maintains an average "Hold" rating with a consensus price target of $361.69. Additionally, recent insider trading shows CFO Maggie Yuen and Director Thomas Wilder selling shares, while the company reported missing EPS estimates in its latest quarterly earnings despite revenue growth.
Penumbra, Inc. (NYSE:PEN) Given Average Rating of "Hold" by Brokerages
Penumbra, Inc. (NYSE:PEN) has an average "Hold" rating from brokerages, with 14 out of 18 analysts recommending a hold and four a buy. The average one-year target price is $361.69. The company recently missed EPS estimates but beat revenue expectations, which rose 22.2% year-over-year.
Penumbra, Inc. (PEN): A bull case theory
This article analyzes Penumbra, Inc. (PEN) from a "bull case" perspective, suggesting reasons why investors might consider it a favorable investment. It likely discusses factors such as growth potential, new product developments, market position, or financial performance that could drive its stock value up. The content would provide an optimistic view of the company's future prospects.
Penumbra (PEN) president has 117 shares withheld for RSU tax obligations
Penumbra Inc.'s President, Shruthi Narayan, reported a tax-withholding share disposition where 117 shares of common stock were withheld to cover tax obligations upon the vesting of restricted stock units. The shares were valued at $336.18 each. Following this non-market event, Narayan directly holds 30,755 Penumbra common shares, with a portion still subject to vesting.
Penumbra (PEN) EVP has 186 shares withheld to cover RSU taxes
Penumbra Inc. EVP Johanna Roberts had 186 shares of Common Stock withheld to cover taxes on vesting restricted stock units, valued at $336.18 per share. This non-market disposition is a routine tax withholding transaction related to equity compensation, not an open-market sale. Following this event, Roberts directly holds 67,298 shares of Penumbra Common Stock, with a portion still subject to vesting.
UBS reiterates Penumbra stock rating on thrombectomy confidence
UBS has reiterated a Neutral rating on Penumbra Inc. (NYSE:PEN) with a $374.00 price target, expressing confidence in the thrombectomy market and Penumbra's position, despite the stock potentially being overvalued. This update follows Penumbra's strong Q4 2025 revenue and adjusted EBITDA, and recent news of Boston Scientific's acquisition of the company for $374 per share, leading to several analyst downgrades but aligned price targets.
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Penumbra (PEN) is identified as a strong growth stock due to its favorable Zacks Growth Style Score and top Zacks Rank. Key factors supporting this recommendation include its impressive historical and projected earnings growth (74.9% historical, 32.2% projected for the current year), robust year-over-year cash flow growth of 52%, and consistently positive earnings estimate revisions from analysts. These indicators suggest Penumbra has strong prospects for outperformance and significant stock price gains.
What Makes Penumbra (PEN) a Good Investment Choice?
Artisan Small Cap Fund recently highlighted Penumbra, Inc. (NYSE: PEN) in its fourth-quarter 2025 investor letter, increasing its position in the medical device company. Penumbra specializes in minimally invasive treatments for blood clots and vascular conditions, with adoption of its core products growing due to strong clinical outcomes and broader physician use. Despite the positive outlook for Penumbra, the fund suggests that some AI stocks may offer greater upside potential in a shorter timeframe.
Jain Global LLC Boosts Stock Position in Penumbra, Inc. $PEN
Jain Global LLC significantly increased its stake in Penumbra, Inc. (NYSE:PEN) by 229.0% in the third quarter, now owning 32,547 shares worth $8.245 million. Other institutional investors have also adjusted their positions in the medical technology company. Despite recent insider selling, analysts maintain a "Hold" rating on Penumbra with an average price target of $361.69, while the company reported mixed Q3 earnings results.
Holocene Advisors LP Makes New Investment in Penumbra, Inc. $PEN
Holocene Advisors LP has initiated a new stake in Penumbra, Inc., acquiring 310,219 shares valued at approximately $78.6 million, representing about 0.79% of the company. This investment comes despite Penumbra missing recent quarterly EPS estimates but exceeding revenue expectations with a 22.2% year-over-year increase. The stock currently holds an average "Hold" rating from analysts with a consensus target price of $361.69.
Delta Global Management LP Acquires 7,896 Shares in Penumbra, Inc.
Delta Global Management LP has acquired 7,896 shares of Penumbra, Inc. (NYSE:PEN) during the third quarter, valued at approximately $2,000,000. This move signals the investment firm's confidence in the medical device company's future growth, which specializes in neurovascular and peripheral vascular conditions. Other institutional investors have also adjusted their holdings in Penumbra, whose stock has shown strong performance over the past year.
Delta Global Management LP Purchases Shares of 7,896 Penumbra, Inc. $PEN
Delta Global Management LP has acquired a new position in Penumbra, Inc. (NYSE:PEN) during the third quarter, purchasing 7,896 shares valued at approximately $2,000,000. Other institutional investors also modified their holdings, and insiders have sold shares totaling over $948,000 in the last three months. Analyst ratings for Penumbra are predominantly "Hold," with an average target price of $361.69.
Bamco Inc. NY Has $3.42 Million Position in Penumbra, Inc. $PEN
Bamco Inc. NY significantly reduced its stake in Penumbra, Inc. by 22.9% in the third quarter, now holding 13,500 shares valued at $3.42 million. This comes after company insiders also sold a substantial number of shares, including CFO Maggie Yuen. Despite these sales, analysts maintain a consensus "Hold" rating on Penumbra, with an average price target of $361.69, even though the company recently missed EPS estimates but saw a 22.2% increase in revenue.
Algert Global LLC Buys 12,830 Shares of Penumbra, Inc. $PEN
Algert Global LLC increased its stake in Penumbra, Inc. (NYSE:PEN) by 38.8% in the third quarter, purchasing an additional 12,830 shares, bringing its total holdings to 45,875 shares valued at $11.62 million. Other institutional investors have also adjusted their positions in the company, which recently reported an EPS of ($0.37) against an estimated $1.12, although revenue exceeded analyst expectations. The stock currently carries an average "Hold" rating from analysts with an average price target of $361.69.
Braidwell LP Has $35.85 Million Stock Position in Penumbra, Inc. $PEN
Braidwell LP increased its stake in Penumbra, Inc. (NYSE:PEN) by 9.2% in the third quarter, bringing its total holdings to 141,528 shares valued at $35.85 million. This investment represents 1.1% of Braidwell LP's portfolio and makes Penumbra its 28th largest holding. Despite institutional investors owning 88.88% of the stock, insiders have recently sold shares worth over $948,000, and analysts currently have a "Hold" rating on Penumbra with an average target price of $361.69.
Integral Health Asset Management LLC Has $12.67 Million Stock Position in Penumbra, Inc. $PEN
Integral Health Asset Management LLC has increased its stake in Penumbra, Inc. (NYSE:PEN) by 25% to 50,000 shares, now valued at $12.67 million. This move comes despite Penumbra reporting an EPS miss but a revenue beat in its latest quarterly earnings. Analyst consensus remains a "Hold" for the company, while insiders have been net sellers in recent months.
Magnetar Financial LLC Sells 26,473 Shares of Penumbra, Inc. $PEN
Magnetar Financial LLC significantly reduced its stake in Penumbra, Inc. (NYSE:PEN) by selling 26,473 shares, leaving it with 5,163 shares valued at over $1.3 million. Additionally, Penumbra's CFO Maggie Yuen and other insiders have sold shares recently, totaling $948,419 in the last 90 days. Despite an EPS miss, Penumbra exceeded revenue expectations, and analysts currently rate the stock as a "Hold" with an average target price of $361.69.
Capital World Investors Sells 129,455 Shares of Penumbra, Inc. $PEN
Capital World Investors reduced its stake in Penumbra, Inc. (NYSE:PEN) by 23.7%, selling 129,455 shares and now holding 415,732 shares valued at approximately $105.31 million. Penumbra's latest quarterly earnings missed estimates, reporting a loss of $0.37 per share against an expected $1.12, though revenue of $385.39 million surpassed projections with a 22.2% year-over-year increase. Analyst sentiment for PEN is mixed, with an average "Hold" rating and a price target of $361.69, amidst both upgrades and downgrades from various financial firms.
NZS Capital LLC Buys 17,355 Shares of Penumbra, Inc. $PEN
NZS Capital LLC increased its stake in Penumbra, Inc. by 24.9% during Q3, acquiring an additional 17,355 shares to hold a total of 86,984 shares valued at $22.04 million. Other institutions like Invesco, Norges Bank, Qube Research, and Man Group also significantly increased their positions, bringing institutional ownership to 88.88%. Despite beating Q3 earnings and revenue estimates, the stock has an average analyst rating of "Hold" with a target price of $361.69.
Insider Sell: Maggie Yuen Sells Shares of Penumbra Inc (PEN)
Maggie Yuen, CFO of a Penumbra Inc subsidiary, sold 2,432 shares of PEN on March 2, 2026. This transaction continues a pattern of insider selling at Penumbra, with no buys and 48 sells in the past year. Penumbra Inc's stock is currently trading at $342.3, is considered fairly valued based on its GF Value, and has a higher P/E ratio compared to the industry median.
Penumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future
Penumbra (NYSE:PEN) has agreed to be acquired by Boston Scientific in an all-cash transaction valued at approximately US$14.5 billion. This deal shifts investor focus from Penumbra's standalone growth prospects to the terms, timing, and closing risks of the acquisition, while raising questions about the future of the combined product portfolio. Investors should monitor shareholder approval, regulatory clearances, and any changes to the deal structure, considering both the potential for a clear exit value and the shift to a more diversified investment profile.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—THR, PEN, BCO, and ALGT
Monteverde & Associates PC, a class action law firm, is investigating the proposed mergers involving Thermon Group Holdings, Inc. (NYSE: THR), Penumbra, Inc. (NYSE: PEN), The Brink’s Company (NYSE: BCO), and Allegiant Travel Company (NASDAQ: ALGT). The firm, recognized for recovering millions for shareholders, encourages investors with concerns about these transactions to contact them for a free consultation. Shareholders in each company have specific options regarding cash and stock exchanges depending on the merger terms.
Champlain Investment Partners LLC Trims Holdings in Penumbra, Inc. $PEN
Champlain Investment Partners LLC reduced its stake in Penumbra, Inc. (NYSE:PEN) by 3.5% in the third quarter, selling 25,810 shares. Despite the reduction, Penumbra remains Champlain's 13th largest holding, valued at $181.86 million, representing 1.83% ownership. The company recently reported strong Q3 earnings, exceeding analyst expectations with EPS of $1.18 and revenue of $385.4 million, reflecting 22.2% year-over-year growth.
PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise
Penumbra, Inc. (PEN) reported strong fourth-quarter 2025 results, with adjusted EPS of $1.18 and revenues of $385.4 million, both exceeding Zacks Consensus Estimates. The company saw significant year-over-year growth in both earnings and revenues, and gross and operating margins expanded. Despite halting 2026 guidance due to a pending acquisition by Boston Scientific, Penumbra's performance was bolstered by growth in its Thrombectomy and Embolization and Access product segments.
Citigroup Inc. Grows Stock Holdings in Penumbra, Inc. $PEN
Citigroup Inc. significantly increased its stake in Penumbra, Inc. (NYSE:PEN) by 75.9% in the third quarter, bringing its total holdings to 33,560 shares valued at $8.5 million. Other institutional investors like Vanguard, Invesco, and Norges Bank also substantially increased or initiated positions, pushing overall institutional ownership to 88.88%. Despite beating Q3 earnings estimates with $1.18 EPS and $385.4 million in revenue, Penumbra trades at a high valuation (PE 76.18) and holds a consensus "Hold" rating from analysts with a target price of $361.69.
Broker files Form 144 reporting PEN share sales (NYSE: PEN)
Morgan Stanley Smith Barney LLC filed a Form 144 on behalf of Penumbra Inc (PEN) to report proposed sales of common stock. The filing details specific share lots and their acquisition dates, including shares from exercised options, restricted stock, and an Employee Stock Purchase Plan. The notice is routine for Rule 144, but does not disclose sale prices, transaction timing, or the identity of the seller.
(PEN) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Penumbra Inc. (NYSE: PEN), noting neutral near and mid-term readings but a positive long-term bias. It outlines detailed institutional trading strategies including long, short, and breakout options with specific entry, target, and stop-loss levels. The analysis emphasizes risk-reward ratios and includes multi-timeframe signal assessments generated by AI models.
Penumbra, Inc. (PEN) Stock Analysis: Unveiling the Potential in Medical Devices with a 4.57% Upside
Penumbra, Inc. (PEN) is a prominent medical device innovator with a market capitalization of $13.51 billion, showing robust growth and a 22.10% revenue increase. Analysts have a mixed but cautiously optimistic view, with an average target price pointing to a 4.57% upside given its strong financial health and diversified product portfolio. The company's commitment to innovation and high-performance metrics position it well for future returns in the evolving healthcare landscape.
PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise
Penumbra, Inc. (PEN) reported strong fourth-quarter and full-year 2025 results, with adjusted EPS of $1.18 and revenues of $385.4 million, both exceeding Zacks Consensus Estimates. The company saw significant growth in both its United States and International segments, largely driven by Thrombectomy and Embolization and Access product sales, leading to improved gross and operating margins. Following the announcement of its acquisition by Boston Scientific for $14.5 billion, Penumbra has halted its 2026 financial guidance.
TD Asset Management Inc Sells 8,742 Shares of Penumbra, Inc. $PEN
TD Asset Management Inc. reduced its stake in Penumbra, Inc. (NYSE:PEN) by 8.2% in the third quarter, selling 8,742 shares and retaining 97,528 shares valued at $24.7 million. Insider selling also occurred, with Director Arani Bose selling 15,000 shares for $4.63 million. Penumbra reported strong Q3 earnings, beating analyst expectations with $1.18 EPS and $385.39 million in revenue, leading to a consensus "Hold" rating from analysts with an average target price of $361.69.
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Penumbra, Inc. (NYSE: PEN) announced its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 6:00 PM ET. A webcast of the presentation will be accessible on the company's investor relations website for at least two weeks following the event. Penumbra specializes in developing innovative technologies for challenging medical conditions such as ischemic stroke and venous thromboembolism.
Artisan Partners Limited Partnership Raises Position in Penumbra, Inc. $PEN
Artisan Partners Limited Partnership increased its stake in Penumbra, Inc. by 9.5% in the third quarter, holding 223,476 shares valued at $56.61 million. This move is part of a broader trend of institutional investors, including Thrivent Financial, adding to their positions in Penumbra, with overall institutional ownership reaching 88.88%. Despite recent analyst downgrades, Penumbra beat Q earnings and revenue estimates, reporting $1.18 EPS and $385.39 million in revenue, while insiders have recently engaged in stock sales.
Penumbra, Inc. $PEN Shares Acquired by Intech Investment Management LLC
Intech Investment Management LLC increased its stake in Penumbra, Inc. by 13.3%, now owning 48,971 shares valued at $12.4 million. This acquisition follows Penumbra's strong Q4 earnings, where it surpassed analyst estimates with $1.18 EPS and 22% year-over-year revenue growth. Despite a "Hold" consensus rating and a high P/E ratio of 75.64, institutional investors now hold 88.88% of the company.
Penumbra (PEN) Earnings Surge Challenges Concerns Over Rich 75x P/E Valuation
Penumbra (PEN) reported strong Q4 2025 results with revenue of US$385.4 million and EPS of US$1.21, significantly growing earnings over the past year. Despite this surge and a 12.7% net margin, the company faces scrutiny over its high P/E ratio of 75.5x, which is considerably above industry averages and its DCF fair value. While bulls point to growth potential in underpenetrated therapy areas, bears caution that the current valuation leaves little room for error and suggests a substantial gap between market price and intrinsic value.
